Mylan Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Partes Review Proceedings on All Claims Against Sanofi's Lantus(R) Patents

HERTFORDSHIRE, England and PITTSBURGH, Dec. 14, 2017 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the U.S. Patent and Trademark Appeal Board (PTAB) has instituted inter partes review (IPR) proceedings on... Biopharmaceuticals, Generics, Litigation Mylan, Sanofi, Lantus, insulin glargine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news